Retevmo Treatment for medullary thyroid cancer

Availability in India

The active element in the cancer medication Retevmo is sepercatinib. Adult patients with one of the following conditions are treated with it: locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion; locally advanced or metastatic solid tumors with a RET gene fusion; advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. It exerts its effect via inhibiting kinase.It is also used in pediatric patients over 12 with advanced medullary thyroid cancer.

Retevmo cost in India is inexpensive and can be bought with a valid prescription, so you may get it from various sellers and spend less for the medication. Indian Pharma is one of the most reputable and trusted generic medicine manufacturers. 

Recommended Dosage

Selpercatinib is contained in Retevmo. The patient is chosen based on the presence of a certain RET gene mutation (MTC) or transfection gene rearrangement (NSCLC or thyroid). The dosage of retevmo is regulated by body weight. As a result, before beginning Retevmo medication, the patient's body weight is examined, and the Retevmo dosage is changed as needed. If the patient weighs less than 50 kg, the dose should be 120 mg; if the patient weighs 50 kg or more, the dose should be 160 mg. This medicine requires a prescription, and the therapy should be initiated and overseen by a certified medical specialist.

Dosage & Administration

Retevmo must be administered orally twice a day, approximately every 12 hours until disease progression or severe toxicity is noted. This drug can be taken with or without food unless combined with a proton pump inhibitor. It should be emphasized that Retevmo capsules should not be crushed or chewed but should instead be swallowed whole. If a dose is missed, it should be taken at least 6 hours after the previous dose. Please read the package leaflet or contact us at https://www.indianpharmanetwork.in/contact-us/  if you have any questions about missing Retevmo doses. 

An FDA approved drug

The drug Retevmo conatins Selpercatinib, approved by the FDA in 2020 for treating non-small cell lung cancer. SELPERCATINIB price is reasonable and one can buy this medicine from any liecnesed supplier. This drug is a RET inhibitor that belongs to the tyrosine kinase inhibitor class of cancer medicines. Retevmo inhibits the activity of abnormal proteins in the body. The body produces these proteins due to changes in the RET gene. certain abnormal proteins in people with certain mutations can lead to uncontrolled cell proliferation and malignancy, culminating in tumor formation. Selpercatinib reduces cancer cell growth and spread by blocking proteins.

Common side effects

Despite being a potent cancer treatment, Retevmo has some adverse effects that can be moderate or fatal. The most common adverse reactions seen after using Retevmo are loss of appetite, headache, dizziness, prolonged QT interval, high blood pressure, abdominal pain, diarrhea, nausea, vomiting, constipation, dry mouth, rash, fever, tiredness, oedema, bleeding, and laboratory blood tests showing changes in liver enzymes, decreased platelet and white blood cell count, decreased magnesium, and increased creatinine. One out of every 10 people taking this drug will experience these side effects.

Retevmo's most common main adverse effects are stomach pain, hypersensitivity, diarrhea, and blood tests that show elevations in liver enzymes, indicating liver stress. 

Drug Interactions

Certain drug interactions should be avoided because they can affect the Retevmo dose. Retevmo 40mg/80mg capsules have Some interactions, which are as follows:

Coadministration of acid-reducing medicines should be avoided since it reduces plasma selpercatinib levels and may decrease Retevmo anti-tumor activity.  

Coadministration of strong and moderate CYP3A inhibitors should be avoided since it raises selpercatinib levels in the blood and increases the risk of side effects.

 Strong and moderate CYP3A inducers: Avoid co administration since it lowers drug plasma concentration, which reduces Retevmo's anti-tumor activity.

Substrates for CYP2C8 and CYP3A: They increase plasma Retevmo levels. Co Administration should be avoided at all costs. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Certain P-gp Substrates: it improves Retevmo concentration as well. Coadministration should thus be avoided. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Retevmo: Summary of the medicine

Retevmo works by inhibiting kinases. The chemical formula for selpercatinib is C29H31N7O3, and its molecular weight is 525.61 g/mol. Selpercatinib is a white to light yellow powder that absorbs moisture from the air and is mildly hygroscopic. Selpercatinib's water solubility is pH dependent. It is only marginally soluble at low pH and virtually insoluble at neutral pH. 40 mg and Retevmo 80 mg hard gelatin capsules are available for oral use. Click here to learn more about selpercatinib and its numerous applications/pharmacological actions. Please contact us by phone or text at https://www.indianpharmanetwork.in/contact-us/. 

Storage & Handling of the medicine 

Microcrystalline cellulose and colloidal silicon dioxide are inactive ingredients in each medicine capsule. The 40 mg pill shell contains gelatin, titanium dioxide, ferric oxide black, and black ink. Patients must read the ingredients and notify their doctor if they cause allergies. Furthermore, the active ingredient is selpercatinib. Keep Retevmo capsules at room temperature, between 68°F and 77°F (20°C and 25°C). A Retevmo 40 mg bottle has 60 capsules.

Retevmo: Price in India

Pregnancy- Based on animal research and the mechanism of action of selpercatinib, it has been discovered that when taken by pregnant women, it can actively cause fetal harm. Pregnant women should avoid taking it as a result. Seek medical attention in an emergency. 

Lactation- No information is available on the presence of selpercatinib in milk. There have been no studies on its metabolites in human milk, their effects on breastfed children, or their effects on milk production. However, due to the likelihood of serious adverse reactions in breastfed children, it is recommended that nursing be discontinued during and one week after the last dosage of Retevmo treatment to avoid severe effects on the child.

Retevmo: Clinical studies

One of the most important studies illustrates the effects of sepercatinib. The researchers discovered that Retevmo effectively shrinks tumor size in patients with cancer caused by RET gene abnormalities. Individual effects of selpercatinib (Retevmo) were investigated in this study but not compared to other drugs, dummy therapies, or placebo. The medication shrinks tumors in all cases, whether they are advanced non-small cell lung cancer, advanced thyroid cancer, or advanced medullary thyroid cancer. This great drug is available for purchase from any licensed supplier. Furthermore, the Retevmo cost is inexpensive and reasonable, allowing them to be easily adopted.

This efficient treatment for non-small cell lung and thyroid/medullary thyroid cancer is now available in India. Retevmo treatment can begin after being diagnosed using an FDA-approved test by competent medical health professionals and doctors. It is important to remember that, despite its inexpensive Retevmo price, Retevmo is not a prescription medication. For the sale and purchase of Retevmo, legal authorization and prescription are required. 

Oncaspar (Pegaspargase) Injection for Cancer Treatment

 Oncaspar: Indication and Usage 

Oncaspar is a cancer medication used to treat acute lymphoblastic leukemia (ALL), a cancer of white blood cells known as lymphoblasts, in adults and children. Oncaspar is prescribed in conjunction with other cancer medications. 

• Acute Lymphoblastic Leukaemia (ALL)-

Oncaspar is suggested as part of a multiagent chemotherapeutic routine for the first-line treatment of ALL patients.

•  Acute Lymphoblastic Leukaemia and Asparaginase Hypersensitivity

Oncaspar is used as part of a multiagent chemotherapy regimen to treat individuals with ALL who are allergic to native versions of L'Asparaginase. This efficient drug is widely available and may be obtained from any respectable vendor. In addition, the Oncaspar injection price in India is affordable. Visit  https://www.indianpharmanetwork.in/contact-us/ for further information.

 Dosage 

Oncaspar dosage strength includes Pegaspargase 3750 IU per 5 mL solution in a single-use vial. No more than 2,500 International Units/m2 intramuscularly or intravenously • Coagulopathy is possible. Carry out proper monitoring. More than once every 14 days. When administering intramuscularly, limit the volume at a single injection site to 2 mL; if the volume is larger than 2 mL, utilize multiple injection sites. 

For more information about the Dosage of the drug, you can call us at +91 9310090915; you can also write us at info@indianpharmanetwork.in 

Administration 

While administering Oncaspar intramuscularly, one should limit the volume at a single injection site to 2 mL. Multiple injection sites should be used if the volume to be delivered is larger than 2 mL. Only use one dose per vial; discard any unused product.

Oncaspar should be given intravenously over 1-2 hours in 100 mL of sodium chloride or dextrose injection 5% via an already running infusion. The solution should be used immediately after being diluted for intravenous usage. If immediate usage is not possible, keep the diluted solution refrigerated at 2°C to 8°C (36°F to 46°F). 

Keep infusion bags out of direct sunlight.

Through Indian Pharma Network, you can buy Oncaspar injections at an affordable price. The Indian Pharma Network facilitates access to new products in India. 

Contradiction

Even though oncaspar injections are readily available in the market under valid prescription, there are specific contradictions associated with the drug that needs to be checked before using the drug. 

• A history of severe allergic responses to Oncaspar
• Initial approval in the United States: 1994, history of L-asparaginase therapy for significant thrombosis 
• History of L-asparaginase therapy for pancreatitis 
• History of L-asparaginase therapy resulted in significant hemorrhagic episodes. 

Warnings and Precautions

If any of the following occur, one should stop using Pegaspargase injection-

• Anaphylaxis or other severe allergic responses-

Observe patients for 1 hour after receiving Oncaspar in a place equipped with resuscitation equipment and additional anaphylactic-treatment drugs (for example, epinephrine, oxygen, intravenous steroids, and antihistamines). In patients who have severe allergic reactions, discontinue Oncaspar. 

• Thrombosis-

Patients on Oncaspar may experience serious thrombotic events, including sagittal sinus thrombosis. In patients who have had major thrombotic events, discontinue Oncaspar. 

• Pancreatitis-

Examine people who have abdominal pain for signs of pancreatitis. In individuals with pancreatitis, discontinue Oncaspar.

Glucose intolerance, which might be permanent in some cases, can ensue. 

Adverse effects

Signs of liver problems, reduced blood clotting, high levels of fats in the blood, high levels of blood glucose, and low levels of white blood cells followed by fever are the most common side effects of Oncaspar (which may affect more than one in ten people).

Oncaspar should not be used in patients with severe liver illness, pancreatitis (including pancreatitis caused by past asparaginase treatments), or significant bleeding or substantial blood clots after asparaginase treatment.

You can visit us at https://www.indianpharmanetwork.in/about-us/ to get the product, as you can get Oncaspar in India at economical prices.

Mechanism of Action

Oncaspar's mechanism of action is assumed to be based on the selective death of leukemic cells caused by plasma asparagine depletion. Due to a lack of asparagine synthetase, some leukemic cells cannot synthesize asparagine and must rely on an exogenous source of asparagine to survive. Asparagine depletion, caused by therapy with the enzyme L-asparaginase, destroys the leukemic cells.

On the other hand, normal cells are less impacted by the deficiency since they can synthesize asparagine. 

This powerful pharmaceutical is on the market and may be obtained from any respectable vendor. Furthermore, the Oncaspar price in India is inexpensive. You can contact us at Indian Pharma Network can be reached at +91 93100 90915 

Description

Oncaspar (pegaspargase) is a covalently conjugated L-asparaginase (L-asparagine amidohydrolase) to monomethoxypolyethylene glycol (mPEG). L-asparaginase is a tetrameric enzyme generated by E. coli that consists of identical 34.5 kDa subunits.

Oncaspar is a clear, colorless, preservative-free isotonic sterile solution in phosphate-buffered saline with a pH of 7.3. In water for injection, USP, each milliliter includes 750 150 International Units of pegaspargase, dibasic sodium phosphate, monobasic sodium phosphate, and sodium chloride.

You can easily purchase this drug at effective rates as Pegaspargase injection cost in India, and it is economical through Indian Pharma Network.

 Use in Specific Population 

Pregnancy - Pregnancy Type C. Oncaspar has not been subjected to animal reproduction studies. It is also unknown whether Oncaspar can induce foetal damage or alter reproductive ability when provided to a pregnant woman. Oncaspar should only be given to a pregnant woman if necessary.

 Breastfeeding Mothers

Oncaspar is not known to be excreted in human milk. Oncaspar has the potential for severe adverse reactions in nursing infants, a choice should be made to terminate breastfeeding or discontinue the drug, taking the importance of the treatment to the mother into account. 

Overdosage

Three patients received an intravenous infusion of 10,000 International Units/m2 of Oncaspar. Liver enzyme levels in one patient slightly rose. A second patient experienced a rash 10 minutes after the infusion began, which was managed by administering an antihistamine and slowing down the infusion rate. A third patient did not have any negative responses. 

To know more about the drug or its overdose and Pegaspargase price in India, you can refer to the Indian Pharma Network, which connects patients with legitimate pharmaceutical suppliers, wholesalers, and dealers. One can check us out by clicking at  https://www.indianpharmanetwork.in/contact-us/ 

Acute Myeloid Leukemia Treatment

 The medicine Tibsovo contains ivosidenib, a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. Healthcare professionals recommend Tibsovo 250 mg Tablets in treating patients with acute myeloid leukemia (AML) and cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation. 

Acute Myeloid Leukemia: Blood Cancer

Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. It typically happens when certain genes or chromosomes mutate (change). AML usually affects people aged 60 and older but can also affect younger adults and children. 

Types of Acute Myeloid Leukemia are:

Myeloid leukemia: Cancer in cells that produce neutrophils, a white blood cell. Most people with AML have the myeloid leukemia subtype.

Acute monocytic leukemia (AML-M5): Cancer in cells that produce monocytes, white blood cells.

Acute megakaryocytic leukemia (AMLK): Cancer in cells that produce red blood cells or platelets.

Acute promyelocytic leukemia (APL): Cancer in promyelocytes (immature white blood cells) that keeps these cells from developing.

Prevalence

According to the Cleveland Clinic, Acute myeloid leukemia affects about 4 in 100,000 adults annually. Each year about 1,160 children receive an AML diagnosis. 

Symptoms of Acute myeloid leukemia

Early on, AML symptoms may feel like you have a cold or flu that won’t go away. Acute myeloid leukemia is aggressive. That means you quickly develop new and more noticeable symptoms such as:

• Dizziness.
• Easy bruising or bleeding, including frequent nosebleeds and bleeding gums.
• Fatigue.
• Feeling cold.
• Fever.
• Night sweats.
• Frequent infections or infections that don’t go away.
• Headaches.
• Loss of appetite.
• Unexplained weight loss.
• Pale skin.
• Shortness of breath.
• Swollen lymph nodes.
• Weakness.
• Bone, back or abdominal pain.
• Tiny red spots on your skin.
• Wounds or sores that don’t go away.

Diagnosis

Healthcare providers use several tests to diagnose AML, including genetic tests to identify AML type. Providers typically start with a physical examination. 

• Complete blood count (CBC).
• Peripheral blood smear.
• Bone marrow biopsy.
• Spinal tap
• Genetic tests

Treatments

Chemotherapy

There are three phases to chemotherapy for AML — induction, consolidation and maintenance. Some of the chemotherapy medicines for the treatment of AML are:

• Cytarabine
• Daunorubicin 
• Idarubicin 
• Azacitidine 
• Decitabine 
• Glasdegib 
• Venetoclax 

Consolidation therapy

Consolidation therapy kills any remaining cancerous cells. It lowers the risk of cancer recurrence (coming back). Most people receive high-dose cytarabine (Ara-C) or HiDAC five days each month for three or four months.

Maintenance therapy

Chemotherapy drugs for maintenance therapy may include:

• Azacitidine 
• Decitabine 
• Midostaurin 

Targeted therapy

Providers may use targeted therapy to treat AML that’s come back or hasn’t responded to chemotherapy:

Providers may use chemotherapy drugs midostaurin (Rydapt) or gilteritinib (Xospata) to treat AML patients with an FTL3 gene mutation. About 25% to 30% of people with AML carry this mutation.

They may use enasidenib (IDHIFA) or ivosidenib (Tibsovo) to treat people who have AML caused by a mutation of their X gene.

Unleash Your Inner Glow with Atriance Injection

Atriance: Available in India

Atriance is a cancer medicine available with a legal and authorized prescription under the brand name Nelarabine. Nelarabine is prescribed for patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) who have not responded to or relapsed following at least two chemotherapy regimens. The evidence to support these indications is limited due to small patient populations in particular illness scenarios.

Nelarabine injection in India is available in the market, and any reliable vendor, such as Indian Pharma Network, can provide it at a fair price. Please contact us at +91 93100 90915 to understand more about the drug.

Dosage and Administration

Nelarabine comes in vials of 250 mg. Complete blood counts, including platelets, must be examined on a regular basis, and Nelarabine administration can only be overseen by a clinician who has been educated in the use of cytotoxic medications.

• Adults and adolescents (those above the age of 16): for adults and adolescents 16 years of age and older, a dose of 1,500 mg/m2 nelarabine administered intravenously over two hours on days 1, 3, and 5 and repeated every 21 days is indicated.
• Nelarabine should be given intravenously to children and teens (age 21 and younger) by dripping the vein for an hour every day for five days, then every three and a half weeks.

Because the Nelarabine injection price is low, this antineoplastic drug is widely available on the market and may be obtained at reasonable costs. 

Side Effects of the drug

The safety profile for Atriance Nelarabine at the approved doses in adults (1,500 mg/m2) and children (650 mg/m2) is based on data from 103 adults and 84 pediatric patients from pivotal clinical studies. Fatigue, gastrointestinal issues, hematological issues, respiratory issues, nervous system concerns (somnolence, peripheral neurological disorders [sensory and motor], dizziness, hypoaesthesia, paraesthesia, headache), and pyrexia were the most common adverse effects. The adverse consequence of nelarabine therapy that is dose-limiting is neurotoxicity. Overdose of nelarabine has no known therapy. Acceptable clinical practice requires the provision of supportive care. As a result, it is vital to follow the dosage instructions and report any side effects as soon as possible.

Atriance: Composition

Atriance infusion solution is a clear, colorless fluid. It comes in transparent glass vials with rubber stoppers and aluminum lids. The active ingredient is nelarabine. Atriance solution for infusion contains 5 mg of nelarabine per milliliter. Atriance 250 mg contains nelarabine in each vial. Sodium hydroxide, injection water, hydrochloric acid, and sodium chloride are among the other constituents ("Atriance contains sodium").

Mechanism of Action

Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. Adenosine deaminase (ADA) rapidly demethylates nelarabine to ara-G, which is subsequently intracellularly phosphorylated by deoxyguanosine kinase and deoxycytidine kinase to yield nelarabine's 5'-monophosphate metabolite. The active 5'-triphosphate form, ara-GTP, is then formed from the monophosphate metabolite. Ara-GTP primarily binds to deoxyribonucleic acid (DNA) in leukemic blasts, reducing DNA synthesis. Cells die as a result of this. The cytotoxic effects of Atriance injection could be mediated by a variety of mechanisms. T-cells are more vulnerable to the cytotoxic effects of nelarabine in vitro than B-cells. 

Warnings And Precautions

•  Nelarabine use has been linked to severe neurological symptoms. Peripheral neuropathy, hypoesthesia (which can range from numbness and paresthesias to motor weakness and paralysis), altered mental states such as severe somnolence, confusion, and coma, and effects on the central nervous system such as convulsions, ataxia, and status epilepticus have all been reported.
• Ascending peripheral neuropathies similar to Guillain-Barré Syndrome have also been documented, as have reactions related to demyelination. (See Section 4.8).
• Neurotoxicity is the dose-limiting danger of nelarabine. Withdrawal from nelarabine has not always resulted in complete recovery from these effects. Nelarabine must be discontinued at the first sign of NCI CTCAE Grade 2 or higher neurological reactions, making frequent monitoring for neurological events highly recommended.

Please visit https://www.indianpharmanetwork.in/  for more information about Nelarabine price. Indian Pharma Network only offers drugs that require a prescription from a licensed physician and does not sell narcotics or sedatives.

 Drug Interactions

Despite the low Atriance price, there are some drug interactions associated with Atriance injection. 

It is not suggested to take nelarabine with adenosine deaminase inhibitors like pentostatin at the same time. Concurrent use of nelarabine may impair its effectiveness and/or affect the adverse event profile of any active medicine.

It can be proved to be beneficial when the drug is used in line with the health practitioner's advice.

Use in Specific Population

• Pregnancy- There is no or little data on the usage of nelarabine in pregnant women.

Animal studies have revealed reproductive harm (see section 5.3). The potential risk to people is unknown; nevertheless, exposure during pregnancy is likely to result in fetal abnormalities and deformities. Nelarabine should be avoided during pregnancy unless absolutely required. If a patient falls pregnant while using nelarabine, they should be warned of the potential risks to the fetus.

• Lactation- The presence of nelarabine or its metabolites in human breast milk is unknown. A risk to the newborn/infant cannot be ruled out. Breastfeeding should be halted when using Atriance.

You can refer us to ask for more information about the drug. We will be happy to help as we are the most trusted supplier. You can also buy Atriance online from Indian Pharma Networks. Visit us at https://www.indianpharmanetwork.in/ for further assistance.

Effect on Fertility

The effect of nelarabine on human fertility is unknown. Unwanted consequences on fertility are possible based on the compound's pharmacological activity. As needed, patients should be counseled about family planning.

During nelarabine treatment, both sexually active men and women should use effective contraceptive techniques. Men who have partners who are pregnant or may get pregnant should use condoms during nelarabine treatment and for at least three months after stopping the medication.

To know more about Atriance injection cost, Indian Pharma Networks offers the most reliable and efficient rates, so you can truly rely on this.

 Precautions for Disposal and other handling

The following measures should be followed for the handling and disposal of cytotoxic anti-tumor medical products: 

• Staff should be instructed on how to handle and transfer the medicinal product.
• Pregnant employees should not be allowed to work with this medication.
• Personnel handling/transferring this therapeutic product should wear protective clothing, including a mask, goggles, and gloves.
• All administrative or housekeeping things, including gloves, should be placed in high-risk waste disposal bags for cremation at high temperatures. Any liquid waste generated during the preparation of the nelarabine solution for infusion should be flushed with a significant volume of water. Accidental skin or eye contact should be treated immediately with substantial amounts of water. Any unused medication or rubbish should be disposed of in accordance with local regulations.

Now, you can buy Atriance injection online in India at very pocket-friendly rates through Indian Pharma Network by visiting us at https://www.indianpharmanetwork.in/. We are a group of highly qualified professionals in the pharmaceutical Industry having more than 20 years of experience in Specialty Pharmaceutical distribution.

Use in Elderly Patients

Although the Atriance injection price is inexpensive, this medication is being monitored more closely. This will enable the rapid detection of new safety information. Any potential adverse reactions should be reported by healthcare experts. Clinical studies of nelarabine did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In an exploratory analysis, increasing age, especially age 65 years and older, appeared to be associated with increased rates of neurological adverse events.

It comes as Atriance 250mg 50 ml, but sometimes overdosing can happen. Although, there have been no reports of overdoses. In clinical studies, nelarabine was given to a pediatric patient at a dose of 75 mg/kg (approximately 2,250 mg/m2) daily for 5 days to 5 adult patients at a dose of 60 mg/kg (approximately 2,400 mg/m2) daily for 5 days, and to a further 2 adults on days 1, 3 and 5. Overdose of nelarabine is likely to cause severe neurotoxicity (perhaps including paralysis and coma), myelosuppression, and death. Two patients had substantial grade 3 ascending sensory neuropathy at a dose of 2200 mg/m2 given on days 1, 3, and 5 every 21 days. The two patients' MRIs revealed results consistent with a demyelinating process in the cervical spine.

Overdose of nelarabine has no recognized antidote. Supportive care should be delivered in accordance with acceptable clinical practice.

Side Effects

• Infections and infestation- In the adult population, there was one further report of biopsy-confirmed progressive multifocal leukoencephalopathy. There have been cases of opportunistic infections, which can be fatal, in individuals taking nelarabine medication.

• Nervous system disorder- There have been reports of episodes associated with demyelination and ascending peripheral neuropathies that look like Guillain-Barré syndrome.
• Neoplasms benign and malignant (including cysts and polyps)-   Tumor lysis syndrome – 7 cases
• And there are some general Blood and lymphatic system disorders, Metabolism and nutrition disorders, Psychiatric and nervous system disorders, eye, vascular, Respiratory, thoracic and mediastinal disorders, Hepatobiliary disorders, Musculoskeletal and connective tissue disorders, and General disorders, and administration site conditions. Atriance injection cost in India is highly economical and can be purchased under fair prices.

Reproduction toxicity As given at levels approximately 24% of the adult human dose on an mg/m2 basis during organogenesis, nelarabine induced increased occurrences of fetal malformations, abnormalities, and variations in rabbits as compared to controls. Cleft palate was seen in rabbits given around twice the adult human dose, absent policies in rabbits given roughly 79% of the adult human dose, and absent gallbladder, accessory lung lobes, fused or additional sternebrae, and delayed ossification at all doses. Rabbits given a dose roughly double the adult human dose had lower maternal and fetal body weight gain.